Treating menopause — MHT and beyond

  title={Treating menopause — MHT and beyond},
  author={Susan R. Davis and Rodney J Baber},
  journal={Nature Reviews Endocrinology},
  pages={490 - 502}
Every woman who lives past midlife will experience menopause, which, by definition, is complete cessation of ovarian function. This process might occur spontaneously (natural menopause) or be iatrogenic (secondary menopause), and can be further classified as ‘early’ if it occurs before the age of 45 years and ‘premature’ if it occurs before the age of 40 years. Globally, the mean age of natural menopause is 48.8 years, with remarkably little geographic variation. A woman’s age at menopause… 

Yin Huo Tang, a traditional Chinese herbal formula, relives ovariectomy and empty bottle stimulation-induced menopause-like symptoms in mice

Network pharmacology and molecular docking analyses revealed that the estrogen signaling pathway might play a key role in attenuating menopause-like symptoms and provided a rationale for using it as a potential therapeutic strategy.

Vaginal atrophy: what is it and how can it be treated?

Practice nurses need to be comfortable asking sensitive questions and be able to give advice and signpost women to relevant and up to date information to promote comfort and ensure that symptoms are reduced.




The menopause transition manifests as a series of symptom complexes that follow a somewhat predictable pattern over a highly variable time course, which varies markedly across individuals and cultures.

Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis.

A higher risk of CHD, CVD mortality, and overall mortality in women who experience premature or early-onset menopause is indicated by a systematically review and meta-analyze of studies evaluating studies evaluating the effect of age at onset of Menopause and duration since onset ofMenopause on intermediate CVD end points,CVD outcomes, and all-cause mortality.

Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis.

Both EM and POI are associated with increased risk of type 2 diabetes mellitus (T2DM).

Understanding weight gain at menopause

There is strong evidence that estrogen therapy may partly prevent this menopause-related change in body composition and the associated metabolic sequelae and further studies are required to identify the women most likely to gain metabolic benefit from menopausal hormone therapy in order to develop evidence-based clinical recommendations.

2016 IMS Recommendations on women’s midlife health and menopause hormone therapy

In preparing these international recommendations, experts have taken into account geographical variations in medical care, prevalence of diseases, and country-specific attitudes of the public, medical community and health authorities towards menopause management.

Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors

Nonhormone options and therapies are available for treatment of estrogen depletion symptoms and clinical problems after a diagnosis of breast cancer and individualization of treatment is essential.

Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression

The increase in CHD events associated with initiating hormone therapy 10 or more years after menopause seems to be related to up-regulation of the plaque inflammatory processes and plaque instability and may be down-regulated by statin pretreatment.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

The use of conjugated equine estrogen (CEE) increases the risk of stroke, decreases therisk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years, indicating no overall benefit.

The role of anxiety and hormonal changes in menopausal hot flashes

A randomly identified, population-based cohort of midlife women followed up for 6 years to assess reproductive hormones and other physical, emotional, and behavioral factors found anxiety preceded hot flashes in this cohort.